FERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION

P Novel bispecific antibody with a dual mechanism of action targeting anemia of inflammation in chronic kidney disease, autoimmune disease, and cancer Experienced leadership and…
posteditor
posteditor
Articles: 27509